Plus Therapeutics Inc. (PSTV)
1.19
0.01 (0.85%)
At close: Jan 15, 2025, 11:50 AM
undefined% (undefined)
| Bid | 1.18 |
| Market Cap | 7.02M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.37 |
| PE Ratio (ttm) | -0.5 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.19 |
| Volume | 2,937 |
| Avg. Volume (20D) | 76,329 |
| Open | 1.18 |
| Previous Close | 1.18 |
| Day's Range | 1.18 - 1.20 |
| 52-Week Range | 0.93 - 2.67 |
| Beta | undefined |
About PSTV
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to d...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 11, 2001
Employees 20
Stock Exchange NASDAQ
Ticker Symbol PSTV
Website https://www.plustherapeutics.com
Analyst Forecast
According to 2 analyst ratings, the average rating for PSTV stock is "Buy." The 12-month stock price forecast is $13.5, which is an increase of 1034.45% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Plus Therapeutics Inc. is scheduled to release its earnings on Mar 4, 2025,
during market hours.
Analysts project revenue of $1.19M, reflecting a -9.37% YoY shrinking and earnings per share of -0.51, making a -27.14% decrease YoY.
Analysts project revenue of $1.19M, reflecting a -9.37% YoY shrinking and earnings per share of -0.51, making a -27.14% decrease YoY.
